

(20144)

Medical Benefit		Effective Date: 07/01/15	Next Review Date: 03/19
Preauthorization	No	Review Dates: 09/07, 09/08, 09/09, 05/10, 03/11, 03/12, 03/13, 03/14, 03/15, 03/16, 03/17, 03/18	

Preauthorization is not required.

The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient's contract at the time the services are rendered.

Populations	Interventions	Comparators	Outcomes
Individuals: <ul style="list-style-type: none"> With nonhyperkeratotic actinic keratoses on the face or scalp 	Interventions of interest are: <ul style="list-style-type: none"> Photodynamic therapy 	Comparators of interest are: <ul style="list-style-type: none"> Pharmacologic therapy Cryotherapy Laser therapy 	Relevant outcomes include: <ul style="list-style-type: none"> Symptoms Change in disease status Quality of life Treatment-related morbidity
Individuals: <ul style="list-style-type: none"> With low-risk basal cell carcinoma 	Interventions of interest are: <ul style="list-style-type: none"> Photodynamic therapy 	Comparators of interest are: <ul style="list-style-type: none"> Pharmacologic therapy Cryotherapy Surgery Radiotherapy 	Relevant outcomes include: <ul style="list-style-type: none"> Symptoms Change in disease status Quality of life Treatment-related morbidity
Individuals: <ul style="list-style-type: none"> With squamous cell carcinoma in situ 	Interventions of interest are: <ul style="list-style-type: none"> Photodynamic therapy 	Comparators of interest are: <ul style="list-style-type: none"> Pharmacologic therapy Cryotherapy Surgery Radiotherapy 	Relevant outcomes include: <ul style="list-style-type: none"> Symptoms Change in disease status Quality of life Treatment-related morbidity
Individuals: <ul style="list-style-type: none"> With nonmetastatic invasive squamous cell carcinoma 	Interventions of interest are: <ul style="list-style-type: none"> Photodynamic therapy 	Comparators of interest are: <ul style="list-style-type: none"> Cryotherapy Surgery Radiotherapy 	Relevant outcomes include: <ul style="list-style-type: none"> Overall survival Symptoms Change in disease status Quality of life Treatment-related morbidity
Individuals: <ul style="list-style-type: none"> With acne 	Interventions of interest are: <ul style="list-style-type: none"> Photodynamic therapy 	Comparators of interest are: <ul style="list-style-type: none"> Pharmacologic therapy Laser or light therapy 	Relevant outcomes include: <ul style="list-style-type: none"> Symptoms Change in disease status Quality of life Treatment-related morbidity
Individuals: <ul style="list-style-type: none"> With noncancerous dermatologic skin conditions (e.g., hidradenitis suppurativa, mycoses, port wine stain) 	Interventions of interest are: <ul style="list-style-type: none"> Photodynamic therapy 	Comparators of interest are: <ul style="list-style-type: none"> Pharmacologic therapy Cryotherapy Laser therapy 	Relevant outcomes include: <ul style="list-style-type: none"> Symptoms Change in disease status Quality of life Treatment-related morbidity

Description

Photodynamic therapy (PDT) refers to light activation of a photosensitizer to generate highly reactive intermediaries, which ultimately cause tissue injury and necrosis. Photosensitizing agents, administered orally or intravenously, have been used in nondermatologic applications and are being proposed for use with dermatologic conditions such as actinic keratoses and nonmelanoma skin cancers.

Summary of Evidence

For individuals who have nonhyperkeratotic actinic keratoses on the face or scalp who receive PDT, the evidence includes RCTs. Relevant outcomes are symptoms, change in disease status, quality of life, and treatment-related morbidity. Evidence from multiple RCTs has found that PDT improves the net health outcome in patients with nonhyperkeratotic actinic keratoses on the face or scalp compared with placebo or other active interventions. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have low-risk basal cell carcinoma who receive PDT, the evidence includes RCTs and systematic reviews of RCTs. Relevant outcomes are symptoms, change in disease status, quality of life, and treatment-related morbidity. Systematic reviews of RCTs have found that PDT may not be as effective as surgery for superficial and nodular basal cell carcinoma. In the small number of trials available, PDT was more effective than placebo. The available evidence from RCTs has suggested that PDT has better cosmetic outcomes than surgery. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have squamous cell carcinoma in situ who receive PDT, the evidence includes RCTs. Relevant outcomes are symptoms, change in disease status, quality of life, and treatment-related morbidity. RCTs have found that PDT has similar or greater efficacy compared with cryotherapy and 5-fluorouracil. Additionally, adverse events and cosmetic outcomes appear to be better after PDT. Few RCTs have compared PDT with surgery or radiotherapy; as a result, conclusions cannot be drawn about PDT compared with these other standard treatments. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have nonmetastatic invasive squamous cell carcinoma who receive PDT, the evidence includes observational studies and a systematic review of observational studies. Relevant outcomes are overall survival, symptoms, change in disease status, quality of life, and treatment-related morbidity. Conclusions cannot be drawn from small, uncontrolled studies. RCTs are needed to determine the safety and efficacy of PDT for this condition. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have acne who receive PDT, the evidence includes RCTs and a systematic review. Relevant outcomes are symptoms, change in disease status, quality of life, and treatment-related morbidity. The available RCTs have not consistently found significantly better outcomes with PDT compared with other interventions, and a meta-analysis did not find significantly better results with PDT versus placebo. Several trials have found that PDT is associated with high rates of adverse events leading to the cessation of treatment. Trials have tended to have relatively small sample sizes and used a variety of comparison interventions. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have noncancerous dermatologic skin conditions (e.g., hidradenitis suppurativa, mycoses, port wine stain) who receive PDT, the evidence includes case series and systematic reviews of uncontrolled series. Relevant outcomes are symptoms, change in disease status, quality of life, and treatment-related morbidity. RCTs are needed to determine the safety and efficacy of PDT for these conditions. The evidence is insufficient to determine the effects of the technology on health outcomes.

Policy

Photodynamic therapy may be considered **medically necessary** as a treatment of:

- Nonhyperkeratotic actinic keratoses of the face and scalp.
- Low-risk (e.g., superficial and nodular) basal cell skin cancer only when surgery and radiation are contraindicated.
- Bowen disease (squamous cell carcinoma in situ) only when surgery and radiation are contraindicated.

Photodynamic therapy is considered **investigational** for other dermatologic applications, including, but not limited to, acne vulgaris, high-risk basal cell carcinomas, hidradenitis suppurativa, and mycoses.

Photodynamic therapy as a technique of skin rejuvenation, hair removal, or other cosmetic indications would be **cosmetic** and therefore not eligible for coverage.

Policy Guidelines

Surgery or radiation is the preferred treatment for low-risk basal cell cancer and Bowen's disease. If photodynamic therapy is selected for these indications because of contraindications to surgery or radiation, patients and physicians need to be aware that it may have a lower cure rate in comparison with surgery or radiation.

Photodynamic therapy typically involves two office visits: one to apply the topical aminolevulinic acid and a second visit to expose the patient to the blue light. The second physician office visit, performed solely to administer blue light, should not warrant a separate Evaluation and Management service. Photodynamic protocols typically involve two treatments spaced a week apart; more than one treatment series may be required.

Medicare Advantage

The preceding policy statements apply with the exception of the following statement addressing actinic keratosis:

For Medicare Advantage it is **medically necessary** to destroy actinic keratoses by, but not limited to, cryosurgery with liquid nitrogen, curettage, excision, and photodynamic therapy, based on what the physician determines is the best treatment for the patient and the characteristics of the lesions present.

Background

Photodynamic Therapy

PDT refers to light activation of a photosensitizer to generate highly reactive intermediaries, which ultimately cause tissue injury and necrosis. Two common photosensitizing agents are 5-aminolevulinic acid (5-ALA) and its methyl ester, methyl aminolevulinate (MAL). When applied topically, these agents pass readily through abnormal keratin overlying the lesion and accumulate preferentially in dysplastic cells. The agents 5-ALA and MAL are metabolized by underlying cells to photosensitizing concentrations of porphyrins. Subsequent exposure to photoactivation (maximum absorption at 404 to 420 nm and 635 nm, respectively) generates reactive oxygen species that are cytotoxic, ultimately destroying the lesion. PDT can cause erythema, burning, and pain. Healing occurs within 10 to 14 days, with generally acceptable cosmetic results. PDT with topical ALA has been investigated primarily as a treatment of actinic keratoses.

Applications

Photodynamic therapy has also been investigated as a treatment of other superficial dermatologic lesions, such as Bowen disease, acne vulgaris, mycoses, hidradenitis suppurativa, and superficial and nodular basal cell carcinoma (BCC). Moreover, there are some potential cosmetic indications, including skin rejuvenation and hair removal.

Actinic keratoses are rough, scaly, or warty premalignant growths on the sun-exposed skin that are very common in older people with fair complexions, with a prevalence of greater than 80% in fair-skinned people older than 60 years of age. In some cases, actinic keratosis may progress to squamous cell carcinoma. Available treatments for actinic keratoses can be divided into surgical and nonsurgical methods. Surgical treatments used to treat one or a small number of dispersed individual lesions include excision, curettage (either alone or combined with electrodesiccation), and laser surgery. Nonsurgical treatments include cryotherapy, topical chemotherapy (5-fluorouracil [5-FU] or masoprocol creams), chemexfoliation (chemical peels), and dermabrasion. Topical treatments are generally used in patients with multiple lesions and involve extensive areas of skin. Under some circumstances, combinations of treatments may be used.

Nonmelanoma skin cancers are the most common malignancies in the white population. Most often found in light-skinned individuals, BCC is the most common of the cutaneous malignancies. Although BCC tumors rarely metastasize, they can be locally invasive if left untreated, leading to significant local destruction and disfigurement. The most prevalent forms of BCC are nodular BCC and superficial BCC. Bowen disease is a squamous cell carcinoma in situ with the potential for significant lateral spread. Metastases are rare, with less than 5% of cases advancing to invasive squamous cell carcinoma. Lesions may appear on the sun-exposed or covered skin. Excision surgery is the preferred treatment for smaller nonmelanoma skin lesions and those not in problematic areas, such as the face and digits. Other established treatments include topical 5-FU, imiquimod, and cryotherapy.

Regulatory Status

In 1999, Levulan® Kerastick™, a topical preparation of ALA, in conjunction with illumination with the BLU-U™ Blue Light Photodynamic Therapy Illuminator, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of nonhyperkeratotic actinic keratoses of the face and scalp. The product is applied in the physician's office. FDA product code: MVF.

In 2016, the FDA approved Ameluz® (aminolevulinic acid hydrochloride) gel, 10% (BF-200 ALA; Biofrontera AG) in combination with PDT using BF-RhodoLED lamp, to be used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The treatment is to be administered by a health care provider.

A 5-ALA patch technology is available outside of the United States through an agreement between Intendis (now Bayer HealthCare) and Photonamic. The 5-ALA patch is not approved by the FDA.

Another variant of PDT for skin lesions is Metvixia® used with the Aktilite CL128 lamp, each of which received FDA approval in 2004. Metvixia® (Galderma, Switzerland; Photocure, Norway) consists of the topical application of MAL (in contrast to ALA used in the Kerastick™ procedure), followed by exposure with the Aktilite CL128 lamp, a red light source (in contrast to the blue light source in the Kerastick™ procedure). Broadband light sources (containing the appropriate wavelengths), intense pulsed light (FDA product code: ONF), pulsed dye lasers, and potassium-titanyl-phosphate lasers have also been used. Metvixia® is indicated for the treatment of nonhyperkeratotic actinic keratoses of the face and scalp in immunocompetent patients when used with lesion preparation (débridement using a sharp dermal curette) in the physician's office when other therapies are unacceptable or considered medically less appropriate. FDA product codes: GEX and LNK.

Related Protocols

Light Therapy for Psoriasis

Oncologic Applications of Photodynamic Therapy, Including Barrett Esophagus

Photodynamic Therapy for Choroidal Neovascularization

Services that are the subject of a clinical trial do not meet our Technology Assessment Protocol criteria and are considered investigational. *For explanation of experimental and investigational, please refer to the Technology Assessment Protocol.*

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced procedures. **Some of this protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.**

References

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.

1. Pariser DM, Lowe NJ, Stewart DM, et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. *J Am Acad Dermatol.* Feb 2003; 48(2):227-232. PMID 12582393
2. Hauschild A, Stockfleth E, Popp G, et al. Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies. *Br J Dermatol.* May 2009; 160(5):1066-1074. PMID 19222455
3. Szeimies RM, Radny P, Sebastian M, et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study. *Br J Dermatol.* Aug 2010; 163(2):386-394. PMID 20518784
4. Dirschka T, Radny P, Dominicus R, et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo. *Br J Dermatol.* Jan 2012; 166(1):137-146. PMID 21910711
5. Dirschka T, Radny P, Dominicus R, et al. Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis. *Br J Dermatol.* Apr 2013; 168(4):825-836. PMID 23252768
6. Giehl KA, Kriz M, Grahovac M, et al. A controlled trial of photodynamic therapy of actinic keratosis comparing different red light sources. *Eur J Dermatol.* May-Jun 2014; 24(3):335-341. PMID 24876164
7. Rubel DM, Spelman L, Murrell DF, et al. Daylight photodynamic therapy with methyl aminolevulinate cream as a convenient, similarly effective, nearly painless alternative to conventional photodynamic therapy in actinic keratosis treatment: a randomized controlled trial. *Br J Dermatol.* Nov 2014; 171(5):1164-1171. PMID 24861492
8. Neittaanmaki-Perttu N, Karppinen TT, Gronroos M, et al. Daylight photodynamic therapy for actinic keratoses: a randomized double-blinded nonsponsored prospective study comparing 5-aminolaevulinic acid nanoemulsion (BF-200) with methyl-5-aminolaevulinate. *Br J Dermatol.* Nov 2014; 171(5):1172-1180. PMID 25109244

9. Reinhold U, Dirschka T, Ostendorf R, et al. A randomized, double-blind, phase III, multicentre study to evaluate the safety and efficacy of BF-200 ALA (Ameluz((R))) vs. placebo in the field-directed treatment of mild-to-moderate actinic keratosis with photodynamic therapy (PDT) when using the BF-RhodoLED((R)) lamp. *Br J Dermatol*. Oct 2016; 175(4):696-705. PMID 26921093
10. Yazdanyar S, Zarchi K, Jemec GBE. Pain during topical photodynamic therapy - comparing methyl aminolevulinate (Metvix((R))) to aminolaevulinic acid (Ameluz((R))); an intra-individual clinical study. *Photodiagnosis Photodyn Ther*. Aug 02 2017. PMID 28780136
11. Patel G, Armstrong AW, Eisen DB. Efficacy of photodynamic therapy vs. other interventions in randomized clinical trials for the treatment of actinic keratoses: a systematic review and meta-analysis. *JAMA Dermatol*. Dec 2014; 150(12):1281-1288. PMID 25162181
12. Morton C, Campbell S, Gupta G, et al. Intraindividual, right-left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study. *Br J Dermatol*. Nov 2006; 155(5):1029-1036. PMID 17034536
13. Szeimies RM, Stockfleth E, Popp G, et al. Long-term follow-up of photodynamic therapy with a self-adhesive 5-aminolaevulinic acid patch: 12 months data. *Br J Dermatol*. Feb 1 2010; 162(2):410-414. PMID 19804593
14. Serra-Guillen C, Nagore E, Hueso L, et al. A randomized pilot comparative study of topical methyl aminolevulinate photodynamic therapy versus imiquimod 5% versus sequential application of both therapies in immunocompetent patients with actinic keratosis: clinical and histologic outcomes. *J Am Acad Dermatol*. Apr 2012; 66(4):e131-137. PMID 22226430
15. Zane C, Facchinetti E, Rossi MT, et al. A randomized clinical trial of photodynamic therapy with methyl aminolaevulinate vs. diclofenac 3% plus hyaluronic acid gel for the treatment of multiple actinic keratoses of the face and scalp. *Br J Dermatol*. May 2014; 170(5):1143-1150. PMID 24506666
16. Bath-Hextall FJ, Perkins W, Bong J, et al. Interventions for basal cell carcinoma of the skin. *Cochrane Database Syst Rev*. Jan 24 2007(1):CD003412. PMID 17253489
17. Wang H, Xu Y, Shi J, et al. Photodynamic therapy in the treatment of basal cell carcinoma: a systematic review and meta-analysis. *Photodermatol Photoimmunol Photomed*. Jan 2015; 31(1):44-53. PMID 25377432
18. Zou Y, Zhao Y, Yu J, et al. Photodynamic therapy versus surgical excision to basal cell carcinoma: meta-analysis. *J Cosmet Dermatol*. Dec 2016; 15(4):374-382. PMID 27363535
19. Szeimies RM, Ibbotson S, Murrell DF, et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up. *J Eur Acad Dermatol Venereol*. Nov 2008; 22(11):1302-1311. PMID 18624836
20. Rhodes LE, de Rie M, Enstrom Y, et al. Photodynamic therapy using topical methyl aminolevulinate vs. surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. *Arch Dermatol*. Jan 2004; 140(1):17-23. PMID 14732655
21. Rhodes LE, de Rie MA, Leifsdottir R, et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs. surgery for nodular basal cell carcinoma. *Arch Dermatol*. Sep 2007; 143(9):1131-1136. PMID 17875873
22. Roozeboom MH, Arits AH, Mosterd K, et al. Three-year follow-up results of photodynamic therapy vs. imiquimod vs. fluorouracil for treatment of superficial basal cell carcinoma: a single-blind, noninferiority, randomized controlled trial. *J Invest Dermatol*. Aug 2016; 136(8):1568-1574. PMID 27113429
23. Bath-Hextall FJ, Matin RN, Wilkinson D, et al. Interventions for cutaneous Bowen's disease. *Cochrane Database Syst Rev*. Jun 24 2013; 6(6):CD007281. PMID 23794286
24. Morton C, Horn M, Leman J, et al. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or Fluorouracil for treatment of squamous cell carcinoma in situ: Results of a multicenter randomized trial. *Arch Dermatol*. Jun 2006; 142(6):729-735. PMID 16785375
25. Salim A, Leman JA, McColl JH, et al. Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen's disease. *Br J Dermatol*. Mar 2003; 148(3):539-543. PMID 12653747

26. Lansbury L, Bath-Hextall F, Perkins W, et al. Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies. *BMJ*. Nov 04 2013; 347:f6153. PMID 24191270
27. Barbaric J, Abbott R, Posadzki P, et al. Light therapies for acne. *Cochrane Database Syst Rev*. Sep 27 2016; 9:CD007917. PMID 27670126
28. Pariser DM, Eichenfield LF, Bukhalo M, et al. Photodynamic therapy with methyl aminolaevulinate 80 mg g(-1) for severe facial acne vulgaris: a randomized vehicle-controlled study. *Br J Dermatol*. Apr 2016; 174(4):770-777. PMID 26663215
29. Orringer JS, Sachs DL, Bailey E, et al. Photodynamic therapy for acne vulgaris: a randomized, controlled, split-face clinical trial of topical aminolevulinic acid and pulsed dye laser therapy. *J Cosmet Dermatol*. Mar 2010; 9(1):28-34. PMID 20367670
30. Mei X, Shi W, Piao Y. Effectiveness of photodynamic therapy with topical 5-aminolevulinic acid and intense pulsed light in Chinese acne vulgaris patients. *Photodermatol Photoimmunol Photomed*. Apr 2013; 29(2):90-96. PMID 23458393
31. Wiegell SR, Wulf HC. Photodynamic therapy of acne vulgaris using methyl aminolaevulinate: a blinded, randomized, controlled trial. *Br J Dermatol*. May 2006; 154(5):969-976. PMID 16634903
32. Gold M, Bridges TM, Bradshaw VL, et al. ALA-PDT and blue light therapy for hidradenitis suppurativa. *J Drugs Dermatol*. Jan-Feb 2004; 3(1 Suppl):S32-35. PMID 14964759
33. Schweiger ES, Riddle CC, Aires DJ. Treatment of hidradenitis suppurativa by photodynamic therapy with aminolevulinic acid: preliminary results. *J Drugs Dermatol*. Apr 2011; 10(4):381-386. PMID 21455548
34. Calzavara-Pinton PG, Venturini M, Capezzeri R, et al. Photodynamic therapy of interdigital mycoses of the feet with topical application of 5-aminolevulinic acid. *Photodermatol Photoimmunol Photomed*. Jun 2004; 20(3):144-147. PMID 15144392
35. Mostafa D, Tarakji B. Photodynamic therapy in treatment of oral lichen planus. *J Clin Med Res*. Jun 2015; 7(6):393-399. PMID 25883701
36. Yazdani Abyaneh MA, Falto-Aizpurua L, Griffith RD, et al. Photodynamic therapy for actinic cheilitis: a systematic review. *Dermatol Surg*. Feb 2015; 41(2):189-198. PMID 25627629
37. Xiao Q, Li Q, Yuan KH, et al. Photodynamic therapy of port-wine stains: long-term efficacy and complication in Chinese patients. *J Dermatol*. Dec 2011; 38(12):1146-1152. PMID 22032688
38. Zloty D, Guenther LC, Sapijaszko M, et al. Non-melanoma skin cancer in Canada. Chapter 4: Management of basal cell carcinoma. *J Cutan Med Surg*. May-Jun 2015; 19(3):239-248. PMID 25986316
39. Poulin Y, Lynde CW, Barber K, et al. Non-melanoma skin cancer in Canada. Chapter 3: Management of actinic keratoses. *J Cutan Med Surg*. May-Jun 2015; 19(3):227-238. PMID 25926621
40. National Comprehensive Cancer Network (NCCN). NCCN Practice Guidelines in Oncology: Basal cell skin cancer. Version 1.2018. http://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf. Accessed October 18, 2017.
41. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Squamous Cell Skin Cancer. Version 2.2018. https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf. Accessed October 18, 2017.
42. Morton CA, McKenna KE, Rhodes LE, et al. Guidelines for topical photodynamic therapy: update. *Br J Dermatol*. Dec 2008; 159(6):1245-1266. PMID 18945319
43. de Berker D, McGregor JM, Mohd Mustapa MF, et al. British Association of Dermatologists' guidelines for the care of patients with actinic keratosis 2017. *Br J Dermatol*. Jan 2017; 176(1):20-43. PMID 28098380
44. Braathen LR, Morton CA, Basset-Seguín N, et al. Photodynamic therapy for skin field cancerization: an international consensus. *International Society for Photodynamic Therapy in Dermatology*. *J Eur Acad Dermatol Venereol*. Sep 2012; 26(9):1063-1066. PMID 22220503
45. Braathen LR, Szeimies RM, Basset-Seguín N, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. *International Society for Photodynamic Therapy in Dermatology*, 2005. *J Am Acad Dermatol*. Jan 2007; 56(1):125-143. PMID 17190630

46. Centers for Medicare and Medicaid Services. National Coverage Determination (NCD) for Treatment of Actinic Keratosis (250.4). 2011; [https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCAId=238&NcaName=Allogeneic+Hematopoietic+Stem+Cell+Transplantation+\(HSC\)+for+Myelodysplastic+Syndrome&ExpandComments=y&CommentPeriod=0&NCDId=129&ncdver=1&bc=AiAAAAAIEAAA%3D%3D&](https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCAId=238&NcaName=Allogeneic+Hematopoietic+Stem+Cell+Transplantation+(HSC)+for+Myelodysplastic+Syndrome&ExpandComments=y&CommentPeriod=0&NCDId=129&ncdver=1&bc=AiAAAAAIEAAA%3D%3D&). Accessed November 1, 2017.